Results 81 to 90 of about 12,515 (211)

BCR-ABL point mutants isolated from patients with imatinib mesylate–resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90 [PDF]

, 2002
M. Gorre, Katharine Ellwood‐Yen, Gabriela Chiosis, Neal Rosen, Charles L. Sawyers   +4 more
openalex   +1 more source

Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia [PDF]

, 2002
Hagop M. Kantarjian, Susan O’Brien, Jorge E. Cortés, Sergio Giralt, Mary Beth Rios, Jianqin Shan, Francis J. Giles, Deborah A. Thomas, Stefan Faderl, Marcos de Lima, Guillermo Garcia‐Manero, Richard E. Champlin, Ralph B. Arlinghaus, Moshe Talpaz   +13 more
openalex   +1 more source

Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells

Tumor Biology, 2017
Imatinib mesylate, a BCR/ABL fusion protein inhibitor, is the first-line treatment against chronic myelogenous leukemia. In spite of its advantageous viewpoints, imatinib still has genuine impediments like undesirable side effects and tumor resistance ...
Alphy Rose James, BS Unnikrishnan, R Priya, Manu M Joseph, TK Manojkumar, K Raveendran Pillai, R Shiji, GU Preethi, P Kusumakumary, TT Sreelekha   +9 more
doaj   +1 more source

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate–resistant Bcr-Abl kinases [PDF]

, 2002
Markus Warmuth, Nicola Simon, Olga Mitina, Ruth Mathes, Doriano Fabbro, Paul W. Manley, Elisabeth Buchdunger, Karin Forster, Ismail Moarefi, Michael Hallek   +9 more
openalex   +1 more source

Osteoporosis in a 60-Year-Old Male With a History of Chronic Myeloid Leukemia Treated With Imatinib Mesylate. [PDF]

Cureus, 2023
Batra J, Ankireddypalli AR, Kanugula AK, Gorle S, Kaur J.   +4 more
europepmc   +1 more source

Falla cardiaca asociada con el uso de imatinib mesilato: Reporte de un caso Heart failure associated to imatinib mesylate use: Case report

Revista Colombiana de Cardiología, 2008
La cardiotoxicidad por medicamentos es un evento cada vez más frecuente en la práctica clínica diaria. Inhibidores de la proteína de fusión Brc/Abl como el imatinib mesilato, son una nueva herramienta para el tratamiento de algunas neoplasias ...
Clara Saldarriaga, Jairo A Rendón, Juan M Senior   +2 more
doaj  

Compound Mutations in the Abl1 Kinase Cause Inhibitor Resistance by Shifting DFG Flip Mechanisms and Relative State Populations [PDF]

arXiv
The intrinsic dynamics of most proteins are central to their function. Protein tyrosine kinases such as Abl1 undergo significant conformational changes that modulate their activity in response to different stimuli. These conformational changes constitute a conserved mechanism for self-regulation that dramatically impacts kinases' affinities for ...
arxiv  

Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response. [PDF]

Ann Hematol, 2023
Ferreira APS, Seguro FS, Abdo ARN, Santos FM, Maciel FVR, Nardinelli L, Giorgi RR, Ruiz ARL, Ferreira MPS, Rego EM, Rocha V, Bendit I.   +11 more
europepmc   +1 more source

Serial monitoring of BCR–ABL by peripheral blood real‐time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia [PDF]

, 2002
Lihui Wang, Kevin Pearson, Lynne Pillitteri, Julia E. Ferguson, Richard E. Clark   +4 more
openalex   +1 more source

Kaposi's sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy. [PDF]

Clin Case Rep, 2022
D'Addona M, Pezzullo L, Giudice V, Serio B, Baldi C, Zeppa P, Selleri C.   +6 more
europepmc   +1 more source